KIMIA BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.48 INR | -2.81% |
|
-6.54% | +42.61% |
| Sales 2022 | 1.25B 14.94M 1.18B | Sales 2023 | 1.29B 15.38M 1.21B | Capitalization | 1.54B 18.4M 1.45B |
|---|---|---|---|---|---|
| Net income 2022 | -37M -443K -34.91M | Net income 2023 | -93M -1.11M -87.74M | EV / Sales 2022 | 1.79 x |
| Net Debt 2022 | 452M 5.41M 427M | Net Debt 2023 | 580M 6.94M 547M | EV / Sales 2023 | 1.65 x |
| P/E ratio 2022 |
-48
x | P/E ratio 2023 |
-16.4
x | Employees | 241 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 7.83% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.81% | ||
| 1 week | -6.54% | ||
| Current month | +10.95% | ||
| 1 month | +11.05% | ||
| 3 months | +2.70% | ||
| 6 months | +40.73% | ||
| Current year | +42.61% |
1 week
52.31
57.00
1 month
45.0357.50
Current year
33.2058.40
1 year
31.9958.40
3 years
30.2065.80
5 years
19.0565.80
10 years
5.0076.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sameer Goel
CEO | Chief Executive Officer | 49 | 28/03/16 |
Rakesh Chetani
DFI | Director of Finance/CFO | - | 06/09/23 |
Lakshay Prakash
CMP | Compliance Officer | - | 15/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sameer Goel
CEO | Chief Executive Officer | 49 | 28/03/16 |
Jagdeep Dhawan
BRD | Director/Board Member | 53 | 28/03/16 |
Richa Gupta
BRD | Director/Board Member | 43 | 14/04/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 52.48 | -2.81% | 6 793 |
| 19/06/24 | 54 | +0.28% | 6,776 |
| 18/06/24 | 53.85 | -2.92% | 5,025 |
| 14/06/24 | 55.47 | -1.21% | 4,074 |
| 13/06/24 | 56.15 | +2.65% | 2,610 |
Delayed Quote Bombay S.E., June 20, 2024 at 11:00 am
More quotes
Kimia Biosciences Limited is an India-based company, which is engaged in the business of pharmaceutical products. The Company provides its products under various categories: Commercial Active Pharmaceutical Ingredients (APIs), Commercial KSMs, Intermediates & Reagents. The Company's Commercial-APIs products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, dapagliflozin propanediol monohydrate, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartan trihydrate potassium, obeticholic acid and ursodeoxycholic acid. Its Commercial KSMs, Intermediates & Reagents products include Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate, 2,4,5-Trimethoxy Benzoic Acid, Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate, Isopropyl 2-(3-Nitrobenzylidene) Acetoacetate, Choline phosphate chloride calcium, and more.
Sector
Pharmaceuticals
Calendar
11/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +42.61% | 30.63M | |
| +53.97% | 803B | |
| -7.12% | 351B | |
| +18.23% | 324B | |
| +10.72% | 303B | |
| +16.74% | 243B | |
| +2.25% | 228B | |
| +10.97% | 217B | |
| +6.11% | 164B | |
| -4.15% | 155B |
- Stock Market
- Equities
- KIMIABL Stock
